跳至主要内容
临床试验/EUCTR2014-003710-84-GB
EUCTR2014-003710-84-GB进行中(未招募)1 期

The Central Nervous System Effects of Two Different HIV-Integrase Inhibitor Containing Antiretroviral Regimens. - The CNS Integrase Inhibitor Study

Imperial College London0 个研究点目标入组 22 人开始时间: 2014年11月4日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
22

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • HIV-1 infected subjects
  • Signed informed consent
  • No contraindication to lumbar puncture examination on screening MRI of brain.
  • Plasma HIV RNA < 200 copies/mL at screening and on at least one other occasion over the last 3 months
  • Acceptable medical history and laboratory parameters (haematology and chemistry) in the opinion of the investigator
  • On a stable antiretroviral regimen for >4 months comprising of:
  • raltegravir 400mg twice daily
  • tenofovir 245 mg daily
  • emtricitabine 200 mg daily
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 20
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 2

排除标准

  • Existing neurological disease
  • Current history of major depression or psychosis
  • Recent head injury (past three months)
  • Current alcohol abuse or drug dependence
  • Active opportunistic infection or significant co-morbidities

研究者

相似试验